Novo Nordisk asked US regulators to approve the drug for children ages 6 to 11. In the EU, it’s available for adolescents as young as 12.
Novo Nordisk asked US regulators to approve the drug for children ages 6 to 11. In the EU, it’s available for adolescents as young as 12.